{"context":{"query":">>ensembl>>reactome","source_dataset":"ensembl","target_dataset":"reactome"},"stats":{"queried":1,"total":60,"mapped":1},"pagination":{"has_next":false},"schema":"id|name|tax_id|is_disease_pathway","mappings":[{"input":"ENSG00000121879","source":"ENSG00000121879|PIK3CA","targets":["R-HSA-109704|PI3K Cascade|9606|false","R-HSA-112399|IRS-mediated signalling|9606|false","R-HSA-114604|GPVI-mediated activation cascade|9606|false","R-HSA-1236382|Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants|9606|true","R-HSA-1250342|PI3K events in ERBB4 signaling|9606|false","R-HSA-1257604|PIP3 activates AKT signaling|9606|false","R-HSA-1433557|Signaling by SCF-KIT|9606|false","R-HSA-1660499|Synthesis of PIPs at the plasma membrane|9606|false","R-HSA-180292|GAB1 signalosome|9606|false","R-HSA-1839117|Signaling by cytosolic FGFR1 fusion mutants|9606|true","R-HSA-186763|Downstream signal transduction|9606|false","R-HSA-1963642|PI3K events in ERBB2 signaling|9606|false","R-HSA-198203|PI3K/AKT activation|9606|false","R-HSA-201556|Signaling by ALK|9606|false","R-HSA-202424|Downstream TCR signaling|9606|false","R-HSA-2029485|Role of phospholipids in phagocytosis|9606|false","R-HSA-210993|Tie2 Signaling|9606|false","R-HSA-2219530|Constitutive Signaling by Aberrant PI3K in Cancer|9606|true","R-HSA-2424491|DAP12 signaling|9606|false","R-HSA-2730905|Role of LAT2/NTAL/LAB on calcium mobilization|9606|false","R-HSA-373753|Nephrin family interactions|9606|false","R-HSA-389357|CD28 dependent PI3K/Akt signaling|9606|false","R-HSA-416476|G alpha (q) signalling events|9606|false","R-HSA-4420097|VEGFA-VEGFR2 Pathway|9606|false","R-HSA-512988|Interleukin-3, Interleukin-5 and GM-CSF signaling|9606|false","R-HSA-5637810|Constitutive Signaling by EGFRvIII|9606|true","R-HSA-5654689|PI-3K cascade:FGFR1|9606|false","R-HSA-5654695|PI-3K cascade:FGFR2|9606|false","R-HSA-5654710|PI-3K cascade:FGFR3|9606|false","R-HSA-5654720|PI-3K cascade:FGFR4|9606|false","R-HSA-5655253|Signaling by FGFR2 in disease|9606|true","R-HSA-5655291|Signaling by FGFR4 in disease|9606|true","R-HSA-5655302|Signaling by FGFR1 in disease|9606|true","R-HSA-5655332|Signaling by FGFR3 in disease|9606|true","R-HSA-5673001|RAF/MAP kinase cascade|9606|false","R-HSA-6811558|PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling|9606|false","R-HSA-8851907|MET activates PI3K/AKT signaling|9606|false","R-HSA-8853659|RET signaling|9606|false","R-HSA-9009391|Extra-nuclear estrogen signaling|9606|false","R-HSA-9013149|RAC1 GTPase cycle|9606|false","R-HSA-9013404|RAC2 GTPase cycle|9606|false","R-HSA-9027276|Erythropoietin activates Phosphoinositide-3-kinase (PI3K)|9606|false","R-HSA-9028335|Activated NTRK2 signals through PI3K|9606|false","R-HSA-912526|Interleukin receptor SHC signaling|9606|false","R-HSA-912631|Regulation of signaling by CBL|9606|false","R-HSA-9603381|Activated NTRK3 signals through PI3K|9606|false","R-HSA-9607240|FLT3 Signaling|9606|false","R-HSA-9664565|Signaling by ERBB2 KD Mutants|9606|true","R-HSA-9665348|Signaling by ERBB2 ECD mutants|9606|true","R-HSA-9670439|Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants|9606|true","R-HSA-9673767|Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants|9606|true","R-HSA-9673770|Signaling by PDGFRA extracellular domain mutants|9606|true","R-HSA-9680350|Signaling by CSF1 (M-CSF) in myeloid cells|9606|false","R-HSA-9703465|Signaling by FLT3 fusion proteins|9606|true","R-HSA-9703648|Signaling by FLT3 ITD and TKD mutants|9606|true","R-HSA-9725370|Signaling by ALK fusions and activated point mutants|9606|true","R-HSA-9842640|Signaling by LTK in cancer|9606|true","R-HSA-9842663|Signaling by LTK|9606|false","R-HSA-9856530|High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells|9606|false","R-HSA-9927354|Co-stimulation by ICOS|9606|false"]}]}